Filing Flows › Comparisons › ALLR vs JUNS
Allarity Therapeutics vs Jupiter Neurosciences: ALLR and JUNS compared
Allarity Therapeutics is the larger company: $25K of revenue in its latest quarter (Q1 2026) against $24K for Jupiter Neurosciences (Q2 2026).
Where the money goes: ALLR and JUNS
Allarity Therapeutics (ALLR) · Q1 2026
Allarity Therapeutics, Q1 2026: revenue $25K, net loss $2.8M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Jupiter Neurosciences (JUNS) · Q2 2026
Jupiter Neurosciences, Q2 2026: revenue $24K, net loss $2.3M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Allarity Therapeutics (ALLR) | Jupiter Neurosciences (JUNS) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $25K | $24K |
| Operating margin | n/m | n/m |
| Net earnings | −$2.8M | −$2.3M |
| Operating cash flow | −$4.5M | −$2.3M |
Questions
Which is bigger, Allarity Therapeutics or Jupiter Neurosciences?
Allarity Therapeutics is the larger company: $25K of revenue in its latest quarter (Q1 2026) against $24K for Jupiter Neurosciences (Q2 2026).
More: Allarity Therapeutics earnings · how Allarity Therapeutics makes money · Jupiter Neurosciences earnings · how Jupiter Neurosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 15, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.